Dr. Kevin Michael Gallagher, MD

Dr. Gallagher practices at WK Hematology Oncology Associates in Shreveport, Louisiana.

Dr. Gallagher's NPI, 1275776718, was assigned on April 14, 2009. Dr. Gallagher graduated from LSU School of Medicine in Shreveport in 2009. Dr. Gallagher holds Louisiana license 204735.

Dr. Gallagher's primary practice is WK Hematology Oncology Associates, at 2600 Kings Hwy, Shreveport, LA 71103 in Caddo Parish. The practice phone is (318) 212-8620.

Dr. Gallagher's primary practice is WK Hematology Oncology Associates in Shreveport, Louisiana. Dr. Gallagher is also affiliated with Willis Knighton North. The medical group on file is Willis Knighton Genetics. Dmand AI also links Dr. Gallagher to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gallagher practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gallagher's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gallagher is licensed in Louisiana.

Dmand AI lists chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Gallagher treats.

CMS data shows 1,788 Medicare services from Dr. Gallagher across 5 procedure codes in 2024, for 358 Medicare patients. Medicare paid $161,522 for them.

CMS counts 358 Medicare patients who saw Dr. Gallagher in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gallagher's median patient age at 72, with 41% women.

In 2024, Dr. Gallagher wrote 1,487 Medicare Part D claims for 214 patients. 69% of them were for generic drugs. CMS names the drug for 1,195 of them, across 35 drugs with 11 or more claims each, at $5,544,575 in total drug cost. In 2023, CMS named 1,032 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Gallagher for performance year 2024, reported through an alternative payment model (APM). Dr. Gallagher accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 50 papers to Dr. Gallagher, published from 2011 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Hematuria, Urinary Bladder Neoplasms and Fibrosis. Dr. Gallagher has published most often in Eye (Lond). Dr. Gallagher's most frequent co-authors are Chandrikha Chandrasekharan, MD, Eduardo Cesar Gonzalez-Toledo, MD and Nebu V. Koshy, MD.

CMS Open Payments shows 876 general payments to Dr. Gallagher from 62 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. AstraZeneca Pharmaceuticals LP paid the most, $67,178.

Dr. Gallagher graduated from LSU School of Medicine in Shreveport in 2009.

Dr. Gallagher is in network with 10 carriers, including Aetna, Alliant Health Plans and HCSC. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.